



(51) International Patent Classification:
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/GB2021/052162

(22) International Filing Date:
20 August 2021 (20.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2013057.1 21 August 2020 (21.08.2020) GB

(71) Applicants: **OXFORD GENETICS LIMITED** [GB/GB];
Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB). **OXFORD UNIVERSITY INNOVATION LIMITED** [GB/GB]; Buxton Court, 3 West Way, Oxford OX2 0JB (GB).


(72) Inventors: **CAWOOD, Ryan**; c/o Oxford Genetics Limited, Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB). **SU, Weiheng**; c/o Oxford Genetics Limited, Medawar Centre, Robert Robinson Avenue, Oxford Oxfordshire OX4 4HG (GB).

(74) Agent: **DEHNS**; St Bride's House, 10 Salisbury Square, London EC4Y 8JD (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: METHOD OF MAKING RECOMBINANT AAVS

Figure 1



(57) Abstract: The present invention relates to a process for producing recombinant adeno-associated virus (AAV) particles, described herein as trans-pseudotyping. The process involves the production of recombinant AAV particles in first host cells and then in second host cells, wherein first and second AAV *cap* genes are expressed in the first and second host cells, respectively, thus producing first and second recombinant AAV particles which are encapsidated by first and second AAV capsid polypeptides. The first and second recombinant AAV particles have different cell tropisms, preferably towards production cell lines (for high efficiency production of AAVs) and for cells associated with a therapeutic indication (for treatment of such an indication), respectively.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))